A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 08 Feb 2024
At a glance
- Drugs 611-3SBio (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 31 Jan 2024 Status changed from not yet recruiting to recruiting.
- 30 Oct 2023 New trial record